Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib/II study of SHR-9839 injection combined with antitumor therapies in advanced solid tumors
CTR20242020Phase 2Active
- Sponsor
- Hengrui Therapeutics
- Start
- Jul 2024
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of SHR-9839, sponsored by Hengrui Therapeutics. Started Jul 2024; status: active.
02
Drugs
SHR-9839
Beyond the preview
Go deeper on CTR20242020.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20242020.